Richard B. Warren

17.3k total citations · 4 hit papers
344 papers, 8.1k citations indexed

About

Richard B. Warren is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Richard B. Warren has authored 344 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 277 papers in Immunology, 147 papers in Dermatology and 62 papers in Rheumatology. Recurrent topics in Richard B. Warren's work include Psoriasis: Treatment and Pathogenesis (261 papers), Dermatology and Skin Diseases (141 papers) and Autoimmune Bullous Skin Diseases (49 papers). Richard B. Warren is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (261 papers), Dermatology and Skin Diseases (141 papers) and Autoimmune Bullous Skin Diseases (49 papers). Richard B. Warren collaborates with scholars based in United Kingdom, United States and Germany. Richard B. Warren's co-authors include C.E.M. Griffiths, Catherine Smith, Zenas Z N Yiu, Kristian Reich, Andrew Blauvelt, Richard G. Langley, Darren M. Ashcroft, Nick J. Reynolds, Juliet N. Barker and A. David Burden and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Richard B. Warren

314 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bimekizumab versus Secukinumab in Plaque Psoriasis

2021 230 citations Kristian Reich, Richard B. Warren et al. profile →
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

2021 169 citations Kristian Reich, Andrew Blauvelt et al. profile →
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

2024 39 citations Richard B. Warren et al. profile →

Peers

Countries citing papers authored by Richard B. Warren

Since Specialization

Citations

This map shows the geographic impact of Richard B. Warren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard B. Warren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard B. Warren more than expected).

Fields of papers citing papers by Richard B. Warren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard B. Warren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard B. Warren. The network helps show where Richard B. Warren may publish in the future.

Co-authorship network of co-authors of Richard B. Warren

This figure shows the co-authorship network connecting the top 25 collaborators of Richard B. Warren. A scholar is included among the top collaborators of Richard B. Warren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard B. Warren. Richard B. Warren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial 2025 ·Journal of the American Academy of Dermatology ·(unknown), Richard G. Langley, Mark Lebwohl, Bruce Strober, Richard B. Warren, L. Puig, Akimichi Morita, Kenneth B. Gordon, Pablo Fernández‐Peñas, Sarah Kavanagh, (unknown), Jérémy Lambert, Bengt Hoepken, (unknown), Nancy Cross, Diamant Thaçi	1
2	Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre 2025 ·Dermatology and Therapy ·(unknown), (unknown), (unknown), Timothy Clayton, H.J.A. Hunter, Richard B. Warren	0
3	Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis 2025 ·Experimental Dermatology ·Richard B. Warren, Anne Weiss, Jakob Felding, Morten Otto Alexander Sommer, Sandra Garcet, James G. Krueger	0
4	Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial 2024 ·Dermatology and Therapy ·L. Puig, Antonio Costanzo, E.M.G.J. de Jong, Tiago Torres, Richard B. Warren, Robert Wapenaar, Sven Wegner, (unknown), (unknown), (unknown), Jozefien Buyze, Curdin Conrad	0
5	51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trial 2024 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Bruce Strober, Georgios Kokolakis, Joseph F. Merola, Min Zheng, Richard G. Langley, Ming Tang, Patrick Hofmann, Christian Thoma, Richard B. Warren	1
6	51782 Generalized pustular psoriasis (GPP) continues to adversely impact quality of life between flares, as per Dermatology Life Quality Index scores: Baseline data from the Effisayil 2 trial 2024 ·Journal of the American Academy of Dermatology ·Matthias Augustin, Alice B. Gottlieb, Yayoi Tada, L. Puig, Boni E. Elewski, Melinda Gooderham, Richard B. Warren, Ming Tang, Patrick Hofmann, Christian Thoma, April W. Armstrong	1
7	Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison 2024 ·Rheumatology and Therapy ·Philip J. Mease, Richard B. Warren, Peter Nash, Jean‐Marie Grouin, (unknown), V. Taieb, (unknown), Iain B. McInnes	1
8	Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials 2024 ·Dermatology and Therapy ·Joseph F. Merola, Alice B. Gottlieb, Andreas Pinter, Boni E. Elewski, Melinda Gooderham, Richard B. Warren, Stefano Piaserico, (unknown), Nancy Cross, Nicola Tilt, (unknown), Ulrich Mrowietz	2
9	53999 Efficacy and safety after 52 weeks in psoriasis patients switching to risankizumab after suboptimal response to secukinumab or ixekizumab – a subgroup analysis 2024 ·Journal of the American Academy of Dermatology ·Richard B. Warren, Antonio Costanzo, Neil J. Korman, Simone Rubant, (unknown), (unknown), (unknown), Diamant Thaçi	1
10	Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program 2023 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Richard B. Warren, Howard Sofen, (unknown), C. Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, (unknown), Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt	3
11	POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL 2023 ·Annals of the Rheumatic Diseases ·Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, Frank Behrens, Laure Gossec, M. Elaine Husni, Lars Erik Kristensen, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, (unknown), Alice B. Gottlieb	3
12	Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest 2023 ·SKIN The Journal of Cutaneous Medicine ·Kristian Reich, Eric L. Simpson, Richard G. Langley, Richard B. Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, (unknown), Andrew Blauvelt	1
13	Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in Psoriasis 2023 ·Cells ·Peter West, Chiara Tontini, (unknown), (unknown), (unknown), Rajia Bahri, Richard B. Warren, C.E.M. Griffiths, Adam Stevens, Silvia Bulfone‐Paus	6
14	Effect of Subcutaneous Spesolimab on the Prevention of Generalized Pustular Psoriasis Flares Over 48 weeks: Subgroup Analyses from the Effisayil 2 Trial 2023 ·SKIN The Journal of Cutaneous Medicine ·Richard B. Warren, David Burden, Siew Eng Choon, Kenneth B. Gordon, L. Puig, Arash Mostaghimi, Georgios Kokolakis, (unknown), Patrick Hofmann, Christian Thoma, Milan J. Anadkat	2
15	Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies 2023 ·British Journal of Dermatology ·Abhishek Abhishek, Matt Stevenson, Georgina Nakafero, Matthew J. Grainge, Ian Evans, Oras Alabas, Tim Card, Maarten W. Taal, Guruprasad P. Aithal, Christopher P. Fox, Christian Mallen, Daniëlle van der Windt, Richard D Riley, Richard B. Warren, Hywel C Williams	2
16	43754 Efficacy and safety of spesolimab for the treatment of generalized pustular psoriasis flares in hospitalized versus non-hospitalized patients 2023 ·Journal of the American Academy of Dermatology ·Richard B. Warren, Yukari Okubo, Milan J. Anadkat, Peter Wolf, (unknown), Sumner Marshall, Christian Thoma, Min Zheng	1
17	Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) 2023 ·British Journal of Dermatology ·(unknown), Anthony Bewley, Catherine Smith, Teena Mackenzie, C.E.M. Griffiths, Mark Lunt, Richard B. Warren, Zenas Z N Yiu	3
18	Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials 2023 ·British Journal of Dermatology ·Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk De Cuyper, O. Davies, Diamant Thaçi	14
19	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis 2019 ·British Journal of Dermatology ·Zenas Z N Yiu, K.J. Mason, Juliet N. Barker, Philip Hampton, Kathleen McElhone, Catherine Smith, Richard B. Warren, C.E.M. Griffiths, Mark Lunt, A. David Burden, (unknown)	16
20	Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology 2017 ·Journal of Investigative Dermatology ·Amy Foulkes, David Watson, C.E.M. Griffiths, Richard B. Warren, Wolfgang Huber, Michael R. Barnes	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact